Search Results

You are looking at 1 - 10 of 26 items for :

  • "prolactinomas" x
Clear All
Open access

Anastasia P Athanasoulia-Kaspar, Kathrin H Popp and Gunter Karl Stalla

Introduction Case report To emphasize the possible role of dopamine agonists in the development of impulse control disorders that could be potentially devastating for the patient’s life, we report a case of a giant-prolactinoma in a young

Open access

Lijin Ji, Na Yi, Qi Zhang, Shuo Zhang, Xiaoxia Liu, Hongli Shi and Bin Lu

Introduction Prolactinoma is the most common functional pituitary tumor, accounting for approximately 40–60% of functional pituitary tumors ( 1 ). Microadenomas are defined as tumors with a diameter of <1 cm and macroadenomas as having a

Open access

Sarah Byberg, Jesper Futtrup, Mikkel Andreassen and Jesper Krogh

treatment for most patients with prolactinoma. A link between high prolactin levels and cardiovascular mortality would have important clinical implications. According to current guidelines ( 22 ), asymptomatic patients with hyperprolactinemia are not

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

Local Ethical Committee of Messina. The first patient (female, 58 years old), with giant prolactin (PRL)-secreting pituitary adenoma (prolactinoma), received five cycles of 111 In-DTPA-octreotide (total activity 37 GBq) from July 2009 to June 2011

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

Introduction Clinically apparent pituitary adenomas are present in about 1:1000 of the general population in Europe; the most frequent sub-types are prolactinomas, non-secreting adenomas and somatotropinomas, while Cushing’s disease and

Open access

Paula Bruna Araujo, Leandro Kasuki, Carlos Henrique de Azeredo Lima, Liana Ogino, Aline H S Camacho, Leila Chimelli, Márta Korbonits and Monica R Gadelha

with micro or macroadenomas diagnosed until 18 years of age were included. Of these patients, 74 (56%) had acromegaly or gigantism, 38 (28.8%) had prolactinoma, 10 (7.6%) had non-functioning pituitary adenoma (NFPA) and 10 (7.6%) had Cushing’s disease

Open access

Nadine M Vaninetti, David B Clarke, Deborah A Zwicker, Churn-Ern Yip, Barna Tugwell, Steve Doucette, Chris Theriault, Khaled Aldahmani and Syed Ali Imran

the following inclusion criteria: i) seen between January 1, 2006, and June 30, 2014; ii) have any of the following diagnoses: non-functioning pituitary adenoma (NFA), prolactinoma (PRLoma), growth hormone-producing adenoma (GH adenoma

Open access

Shruti Khare, Anurag R Lila, Hiren Patt, Chaitanya Yerawar, Manjunath Goroshi, Tushar Bandgar and Nalini S Shah

Introduction Macroprolactinomas constitute approximately half of all the functioning pituitary macroadenomas (1) . Prolactinoma (majority being microprolactinoma) are usually diagnosed in women aged 20–50 years, with a female:male ratio of 10

Open access

Jintao Hu, Qingbo Chen, Xiao Ding, Xin Zheng, Xuefeng Tang, Song Li and Hui Yang

Background Pituitary adenoma (PA) is the second most common brain tumor. Except for prolactinoma, pituitary tumors associated with acromegaly (growth hormone-secreting) and Cushing’s disease (adrenocorticotropic hormone-secreting) as well as

Open access

Mikkel Andreassen, Anders Juul, Ulla Feldt-Rasmussen and Niels Jørgensen

result in testosterone deficiency at some point ( 6 , 7 ). However, little is known about how and when deterioration of semen quality occurs in these patients. Previous studies have primarily examined semen quality in prolactinoma patients with